首页> 外文期刊>Psoriasis: Targets and Therapy >Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
【24h】

Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients

机译:循环无细胞DNA作为埃及牛皮癣患者的炎症标志物

获取原文
       

摘要

Background: Cell lesion and apoptosis with release of cell-free DNA (CFD) in circulation are associated with chronic inflammation of psoriasis. Objective: The?objective?of?this?study?was?to determine the CFD concentrations in sera of patients with psoriasis, to assess its relationship with disease severity as defined by Psoriasis Area Severity Index (PASI) and other inflammatory biomarkers (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) levels, and to monitor the efficacy of treatment. Patients and Methods: Thirty adult patients with different types of psoriasis (25 vulgaris; 10 mild, 15 moderate and 5 erythroderma; severe) were evaluated during the exacerbation phase of the disease, before starting (T0) and after 12 weeks (T12) of treatment with topical therapy for mild cases, narrowband-ultraviolet light B (NB-UVB) for moderate cases and methotrexate for severe cases. Twenty healthy controls were also involved in the study. The concentrations of CFD in sera were measured before and after treatment by quantitative real time PCR (qPCR) using primers of the human β-globin gene. Results: At T0, all patients presented significant higher levels of ESR (P=0.05) and CFD (P=0.001) compared with controls. Highly significant elevations of all parameters were observed in severe disease (erythroderma) compared to mild/moderate disease (vulgaris). Methotrexate treatment induced highly significant reductions in all inflammatory markers including CFD (P= 0.042) while topical and UV irradiation therapies had no effects. CFD concentrations showed positive correlations with both PASI (r=0.422, P=0.020) and ESR (r=0.321, P=0.023) only before the start of treatment. Conclusion: The level of circulating CFD could be used to monitor psoriasis severity. However, its level cannot be stated for the treatment, except in severe erythrodermic patients upon successful treatment with methotrexate. We recommend validation of a convenient and accurate DNA assay applied directly to biological samples which does not require prior DNA extraction and amplification.
机译:背景:在循环中释放细胞病变和细胞凋亡,循环中的无细胞DNA(CFD)与牛皮癣的慢性炎症有关。目的是?目的?这是什么?研究?是确定牛皮癣患者血清中的CFD浓度,以评估其与牛皮癣面积严重指数(PASI)和其他炎症生物标志物定义的疾病严重程度的关系(C-反应蛋白(CRP)和红细胞沉降率(ESR))水平,并监测治疗的功效。患者和方法:在疾病的加剧期间,在开始(T0)和12周(T12)之前,评估三十个不同类型的牛皮癣患者(25岁的牛皮癣(25例,25岁; 10mild,15个中度和5个射头霉菌;严重)。温和病例局部治疗治疗,窄带 - 紫外线B(NB-UVB)中等病例和甲氨蝶呤进行严重病例。研究也参与了20个健康的对照。使用人β-珠蛋白基因的引物在定量实时PCR(QPCR)之前和之后测量血清中CFD的浓度。结果:与对照相比,所有患者均呈现显着较高水平的ESR(P = 0.05)和CFD(P = 0.001)。与轻度/中度疾病(vulgaris)相比,在严重的疾病(红霉菌)中观察到所有参数的高度显着升高。甲氨蝶呤治疗诱导在包括CFD(P = 0.042)的所有炎症标记中诱导显着减少(P = 0.042),而局部和紫外线照射疗法没有任何影响。 CFD浓度仅在开始之前与PASI(r = 0.422,p = 0.020)和ESR(r = 0.321,p = 0.023)显示正相关。结论:循环CFD水平可用于监测牛皮癣严重程度。然而,除了用甲氨蝶呤成功治疗后,除了严重的红斑狼疮患者之外,其水平无法陈述。我们建议验证直接应用于不需要先前DNA提取和扩增的生物样品的方便和准确的DNA测定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号